Rule 10b-5(b) Misstatement Liability Does Not Depend on a “Fraudulent Scheme,” but PSLRA Scienter Still Requires a Cogent Inference; Rule 9(b) Governs Securities Act Claims Sharing the Same Fraud Narrative

I. Introduction

Sandra Hunter v. Elanco Animal Health Incorporated (7th Cir. Aug. 14, 2026) concerns a proposed securities class action alleging that Elanco’s reported sales strength was driven not by end-user demand but by “channel stuffing”—incentivizing distributors to buy excess inventory to create an appearance of growth.

Plaintiffs (investors) targeted Elanco and senior executives (CEO Jeffrey Simmons; CFO Todd Young), plus additional defendants for Securities Act theories tied to acquisition-related offering materials. The core issues on appeal were whether the proposed second amended complaint plausibly stated: (1) Exchange Act § 10(b)/Rule 10b-5(b) misstatement/omission claims under the PSLRA’s heightened standards; (2) Securities Act §§ 11 and 12(a)(2) claims and the applicable pleading standard (Rule 8 vs. Rule 9(b)); (3) an Item 303 Regulation S-K “known trend” omission; and (4) control-person claims under Securities Act § 15 and Exchange Act § 20(a).

II. Summary of the Opinion

The Seventh Circuit affirmed dismissal with prejudice, holding:

  • Rule 10b-5(b) theory: The district court erred in suggesting plaintiffs must plead that channel stuffing itself was “fraudulent” to pursue Rule 10b-5(b). Misstatement/omission liability under Rule 10b-5(b) turns on whether statements were misleading, not on whether the underlying business practice is independently fraudulent. However, plaintiffs still failed because they did not plead a strong inference of scienter under the PSLRA.
  • Securities Act §§ 11 and 12(a)(2): Because the complaint used the same alleged course of deceptive conduct to support both Exchange Act fraud and Securities Act misstatement claims, the Securities Act claims “sound in fraud” and must satisfy Rule 9(b). Plaintiffs did not argue they could meet Rule 9(b), so dismissal was affirmed.
  • Item 303: Item 303 addresses disclosure of external “trends or uncertainties,” not internal sales strategies; the alleged “move in” approach was an internal strategy and not an Item 303 “trend.”
  • Control-person claims: Exchange Act § 20(a) and Securities Act § 15 claims failed for lack of a viable primary violation.

III. Analysis

A. Precedents Cited and Their Role

1. Pleading posture and PSLRA framework

  • Tellabs, Inc. v. Makor Issues & Rts., Ltd., 551 U.S. 308 (2007) (“Tellabs II”): The court relied on Tellabs II for (i) accepting well-pleaded allegations as true at the dismissal stage and (ii) the PSLRA’s comparative scienter test requiring an inference “cogent and at least as compelling” as nonfraudulent inferences.
  • Makor Issues & Rts., Ltd. v. Tellabs, Inc., 437 F.3d 588 (7th Cir. 2006) (“Tellabs I”): Used for articulation of disclosure principles and the proposition that direct, specific responses to analysts can surpass “puffery” concerns, and for the court’s general treatment of PSLRA pleading.
  • Makor Issues & Rts., Ltd. v. Tellabs Inc., 513 F.3d 702 (7th Cir. 2008) (“Tellabs III”): Central to the scienter analysis and treatment of confidential witnesses; also cited for the proposition that channel stuffing is not inherently fraudulent and can have legitimate business explanations.
  • Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (2005): Provided the six elements of a private Rule 10b-5 action (including scienter and loss causation), framing what plaintiffs had to plead.
  • Ernst & Ernst v. Hochfelder, 425 U.S. 185 (1976): Anchored the scienter definition—intent to deceive, manipulate, or defraud—which the PSLRA requires plaintiffs to plead with particularity.

2. Distinguishing Rule 10b-5(b) (statements) from scheme liability

  • Lorenzo v. Sec. & Exch. Comm'n, 587 U.S. 71 (2019): The court used Lorenzo to emphasize that Rule 10b-5(a), (b), and (c) are independent bases of liability. This supported the panel’s key clarification: a Rule 10b-5(b) claim does not require pleading a fraudulent “scheme.”
  • In re Hain Celestial Grp., Inc. Sec. Litig., 20 F.4th 131 (2d Cir. 2021): Persuasive authority reinforcing that clause (b) focuses on whether statements were materially misleading, not whether the underlying practice was inherently illegal.
  • Janus Cap. Grp., Inc. v. First Derivative Traders, 564 U.S. 135 (2011): Cited for the implied private right of action under § 10(b)/Rule 10b-5 and framing private enforcement in the modern doctrine.
  • Sec. & Exch. Comm'n v. Cap. Gains Rsch. Bureau, Inc., 375 U.S. 180 (1963): Cited (via Tellabs I) for the broad disclosure ethic embedded in federal securities regulation.

3. Private enforcement policy and PSLRA purpose

  • Merrill Lynch, Pierce, Fenner & Smith Inc. v. Dabit, 547 U.S. 71 (2006) and Tellabs II: Used to balance the importance of private litigation to market integrity against the risk of abusive suits—context supporting strict PSLRA pleading enforcement.

4. Puffery and context of statements

  • Eisenstadt v. Centel Corp., 113 F.3d 738 (7th Cir. 1997): Cited for the “mere sales puffery” principle.
  • Tellabs I: Contrasted with Eisenstadt to show that specific, analyst-prompted assurances can be closer to actionable statements than general optimism.

5. Confidential witnesses and discounting anonymous sources

  • Higginbotham v. Baxter Int'l, Inc., 495 F.3d 753 (7th Cir. 2007): Provided the discounting approach for anonymous informants; the panel applied it to most confidential witnesses but treated the vice-president witness (CW4) as less discountable due to position and access.
  • Tellabs III: Supplied the nuance that discounting is contextual; corroborated, access-justified informants can still support strong inferences.

6. “Fraud by hindsight” and motive

  • Fulton Cnty. Emps. Ret. Sys. v. MGIC Inv. Corp., 675 F.3d 1047 (7th Cir. 2012): Reinforced that later business reversals do not retroactively establish securities fraud.
  • Pension Tr. Fund for Operating Eng'rs v. Kohl's Corp., 895 F.3d 933 (7th Cir. 2018): Used to discount generic motives (executives always want higher stock prices), limiting motive’s contribution to scienter.

7. Rule 9(b) and “sounds in fraud” doctrine for Securities Act claims

  • Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007), Ashcroft v. Iqbal, 556 U.S. 662 (2009), and Swanson v. Citibank, N.A., 614 F.3d 400 (7th Cir. 2010): Provided the Rule 8 plausibility baseline, contrasted with Rule 9(b).
  • Borsellino v. Goldman Sachs Grp., Inc., 477 F.3d 502 (7th Cir. 2007) and Kennedy v. Venrock Assocs., 348 F.3d 584 (7th Cir. 2003): Anchored the Seventh Circuit’s principle that Rule 9(b) applies to “averments of fraud” even if the statute does not require intent, and that mixed theories require separating fraud from non-fraud allegations—unless the gravamen is a unified fraudulent course of conduct.
  • Cozzarelli v. Inspire Pharms., Inc., 549 F.3d 618 (4th Cir. 2008), Rombach v. Chang, 355 F.3d 164 (2d Cir. 2004), Rubke v. Capitol Bancorp Ltd., 551 F.3d 1156 (9th Cir. 2009), and Cal. Pub. Emps.' Ret. Sys. v. Chubb Corp., 394 F.3d 126 (3d Cir. 2004): Persuasive authority supporting the panel’s rule: when Securities Act claims are pled as part of the same “scheme” alleged under Rule 10b-5, Rule 9(b) applies despite negligence labels or express disclaimers.
  • Sears v. Likens, 912 F.2d 889 (7th Cir. 1990): Cited to show the Seventh Circuit’s willingness to apply Rule 9(b) in Securities Act contexts.
  • In re NationsMart Corp. Sec. Litig., 130 F.3d 309 (8th Cir. 1997) and Lonestar Ladies Inv. Club v. Schlotzsky's Inc., 238 F.3d 363 (5th Cir. 2001): Discussed as counterpoints; the panel distinguished Lonestar and declined to follow NationsMart’s express-disavowal approach.
  • In re Stac Elecs. Sec. Litig., 89 F.3d 1399 (9th Cir. 1996): Used for the “gravamen is plainly fraud” framing.
  • Pirelli Armstrong Tire Corp. Retiree Med. Benefits Tr. v. Walgreen Co., 631 F.3d 436 (7th Cir. 2011): Supported Rule 9(b)’s policy goals—preventing “sue first, ask questions later” fraud pleading.
  • Bradley v. Village of University Park, 59 F.4th 887 (7th Cir. 2023): Cited to justify not developing plaintiffs’ unmade argument that their allegations satisfy Rule 9(b).

8. Securities Act strict/nearly strict liability and Item 303

  • Herman & MacLean v. Huddleston, 459 U.S. 375 (1983): Cited for the concept that § 11 can impose “virtually absolute” liability even for innocent misstatements (contrasting with Exchange Act scienter requirements).
  • Panther Partners Inc. v. Ikanos Commc'ns, Inc., 681 F.3d 114 (2d Cir. 2012): Cited for the similar function of § 12(a)(2).
  • Macquarie Infrastructure Corp. v. Moab Partners, L.P., 601 U.S. 257 (2024), Silverstrand Invs. v. AMAG Pharms., Inc., 707 F.3d 95 (1st Cir. 2013), and Stratte-McClure v. Morgan Stanley, 776 F.3d 94 (2d Cir. 2015): Cited to show Item 303 omissions can support Securities Act claims (and the evolving doctrinal context post-Macquarie).

9. Control-person liability

  • Pugh v. Tribune Co., 521 F.3d 686 (7th Cir. 2008): Stated that Exchange Act § 20(a) requires a well-pled primary violation.
  • Donohoe v. Consol. Operating & Prod. Corp., 30 F.3d 907 (7th Cir. 1994): Applied the same dependency logic to Securities Act § 15.

B. Legal Reasoning

1. The opinion’s principal doctrinal clarification: Rule 10b-5(b) is about statements, not schemes

The court’s most important corrective move is its rejection of the district court’s premise that “only fraudulent channel stuffing is actionable.” By invoking Lorenzo v. Sec. & Exch. Comm'n and the structure of Rule 10b-5, the panel separated: (i) “scheme” liability (Rule 10b-5(a), (c)), from (ii) “statement/omission” liability (Rule 10b-5(b)). Even if channel stuffing can be lawful (as Tellabs III recognizes), statements that attribute revenue to “underlying demand” may still be actionable if they omit facts needed to make those statements not misleading.

Practically, this prevents a categorical defense strategy—“the practice isn’t illegal, so our statements about it can’t be misleading”—from short-circuiting Rule 10b-5(b) analysis.

2. Scienter remains the gating element under the PSLRA

Despite agreeing that the district court used the wrong frame for misstatements, the panel affirmed because the complaint did not clear the PSLRA’s “strong inference” bar for scienter under Tellabs II. The court conducted the required comparative exercise and concluded the most compelling inference was not intentional deception but pursuit of a lawful sales strategy that appeared to be working.

  • Confidential witnesses: Following Higginbotham v. Baxter Int'l, Inc., the panel discounted allegations from witnesses who lacked access to executive intent, while treating the vice-president witness (CW4) as more reliable under Tellabs III.
  • Returns and sustainability: The panel stressed that channel stuffing becomes fraud “only when it is used … to book revenues” on goods not truly sold because they can be returned (Tellabs III). Here, returns were low and declining, undermining an inference that executives knew sales were illusory.
  • Generic motive is not enough: Alleged motivations tied to acquisitions and offerings did not materially strengthen scienter because executives always want strong stock prices and the timing did not fit neatly (Pension Tr. Fund for Operating Eng'rs v. Kohl's Corp.).
  • No “fraud by hindsight”: The later inventory reduction did not retroactively show earlier intent to deceive (Fulton Cnty. Emps. Ret. Sys. v. MGIC Inv. Corp.).

3. Securities Act pleading: one narrative of deception triggers Rule 9(b)

The panel adopted (and aligned the Seventh Circuit with) the widely held rule that when §§ 11 and 12(a)(2) claims are pled using the same alleged deceptive course of conduct as a Rule 10b-5 fraud theory, the Securities Act claims “sound in fraud” and must satisfy Rule 9(b), regardless of disclaimers. It grounded this in Seventh Circuit doctrine that Rule 9(b) applies to “averments of fraud” (Borsellino v. Goldman Sachs Grp., Inc.; Kennedy v. Venrock Assocs.) and reinforced it with multi-circuit authority (Rombach v. Chang; Cozzarelli v. Inspire Pharms., Inc.; Rubke v. Capitol Bancorp Ltd.; Cal. Pub. Emps.' Ret. Sys. v. Chubb Corp.).

The court rejected a loophole whereby plaintiffs could plead an overall fraud story but label Securities Act counts “negligence” to obtain Rule 8 pleading. This is consistent with Rule 9(b)’s deterrence rationale emphasized in Pirelli Armstrong Tire Corp. Retiree Med. Benefits Tr. v. Walgreen Co..

4. Item 303: “known trends” are external, not internal playbooks

The panel treated the alleged “move in” approach as an internal sales strategy rather than an external “known trend or uncertainty,” relying on Stratte-McClure v. Morgan Stanley for the distinction and for the policy concern that Item 303 should not force disclosure of proprietary strategies to competitors. Although Item 303 omissions can be actionable via Securities Act claims (Macquarie Infrastructure Corp. v. Moab Partners, L.P.; Silverstrand Invs. v. AMAG Pharms., Inc.), the court found no Item 303 duty on these alleged facts.

5. Control-person claims fall with the primary claims

Applying Pugh v. Tribune Co. and Donohoe v. Consol. Operating & Prod. Corp., the panel held that without a viable primary Exchange Act or Securities Act violation, secondary control-person liability cannot proceed.

C. Impact

  • Clarifies the analytical sequence for “channel stuffing” cases under Rule 10b-5(b): Courts should not require plaintiffs to prove (or even plausibly plead) that channel stuffing itself is an independently fraudulent “scheme” to evaluate whether statements about “underlying demand” were misleading. This decouples statement-liability analysis from scheme-liability concepts and aligns the Seventh Circuit with the statement-focused approach reflected in In re Hain Celestial Grp., Inc. Sec. Litig..
  • Raises the practical importance of scienter facts showing executives knew the strategy was unsustainable or deceptive: The opinion signals that allegations of internal pressure to “make the quarter,” without more (e.g., evidence of illusory sales, abnormal returns, accounting improprieties, restatements, or concrete executive admissions), may not overcome the competing inference of lawful sales acceleration.
  • Strengthens Rule 9(b) as a gatekeeper for parallel Securities Act claims: Plaintiffs bringing both Exchange Act fraud claims and Securities Act misstatement claims in one complaint should expect Rule 9(b) to govern the Securities Act counts if they share the same alleged deceptive course of conduct—making pleading strategy and count-by-count factual differentiation more consequential.
  • Narrows Item 303 as a tool for challenging internal operational tactics: By characterizing aggressive distribution incentives as an internal strategy rather than an external “trend,” the opinion limits Item 303’s reach in disputes over sales-model shifts.

IV. Complex Concepts Simplified

Channel stuffing
Selling extra product into the distribution chain (to wholesalers/distributors) earlier than true end-user demand would justify. It can be lawful (sales acceleration) or unlawful if used to create fake revenue (e.g., when goods aren’t truly sold because they are likely to be returned).
Rule 10b-5(b) vs. Rule 10b-5(a)/(c)
Rule 10b-5(b) targets misleading statements or omissions. Rule 10b-5(a) and (c) target deceptive schemes or practices. A plaintiff can pursue (b) without proving a “scheme.”
Scienter
The required wrongful state of mind for Exchange Act fraud—intent to deceive (or at least severe recklessness in many formulations). Under the PSLRA, it must be supported by facts that make the fraudulent inference as strong as nonfraudulent explanations.
PSLRA “strong inference”
A heightened pleading rule requiring courts to compare plausible explanations and allow the case to proceed only if the inference of fraudulent intent is cogent and at least as compelling as innocent inferences.
Rule 8 vs. Rule 9(b)
Rule 8 requires a plausible “short and plain statement.” Rule 9(b) requires particularized pleading of the “who, what, when, where, and how” of fraud-like allegations. Even non-fraud statutes (like § 11) can be subjected to Rule 9(b) if the complaint’s substance alleges a unified fraud narrative.
Item 303 “known trends”
A disclosure requirement in MD&A for known trends/uncertainties reasonably likely to affect financial results—typically framed as external developments, not internal tactical choices.
Control-person liability
A secondary liability theory making controlling individuals/entities responsible for a company’s securities violations—but only if there is a viable primary violation.

V. Conclusion

The Seventh Circuit’s decision delivers two major lessons for modern disclosure litigation involving distribution-channel dynamics. First, it clarifies that a Rule 10b-5(b) claim hinges on whether statements were misleading—not on whether the underlying sales practice is independently “fraudulent”—while still enforcing the PSLRA’s demanding scienter requirement where lawful-strategy inferences remain compelling. Second, it reinforces that Securities Act counts will be held to Rule 9(b) when they are pled as part of the same overarching fraud narrative as Exchange Act claims, disclaimers notwithstanding. Finally, it constrains Item 303 by treating internal sales-model choices as outside “known trend” disclosure absent an external trend/uncertainty trigger.